We investigated the in vitro viscoelastic changes of progressive haemodilution with succinylated gelatin (SG) solution compared with normal saline (NS) using rotational thromboelastometry (ROTEM® .4] mm); 58.4% decrease). The platelet contribution to clot strength (EXTEM MCF-FIBTEM MCF) was not changed by SG. We found that haemodilution of more than 20% with SG impaired coagulation greater than that observed with NS haemodilution in this in vitro study. This suggests that at 40% haemodilution with SG, a clinical scenario that could occur during resuscitation of a patient in grade IV haemorrhagic shock, impaired coagulation could occur. Frequent monitoring of coagulation is advised when SG solutions are administered rapidly during volume resuscitation.
Gelatin, one of the first synthetic colloid plasma expanders used for fluid resuscitation, is a breakdown product of collagen 1 . Different modifications of gelatin molecules include succinylated gelatin (SG) (Gelofusine®, Braun, Sydney, New South Wales), urea-linked gelatin (Haemaccel®, Piramal Enterprises, Northumberland, UK) and oxypolygelatin (Polygel®, manufacturer details unknown). Generally, gelatin solutions are considered not to impair surgical haemostasis 2 . Two Cochrane reviews 3, 4 reported no significant mortality associated with gelatin volume expanders in the resuscitation of critically ill patients. However, clinical studies have shown that gelatin solutions can impair blood coagulation by reducing clot strength 5, 6 . Acute hypersensitivity reaction to Gelofusine and other gelatin plasma expanders is well described 7 with an estimated incidence of 0.06% to 0.15%. The aims of this study were to evaluate the direct effects of SG on coagulation and to distinguish between the effects of gelatin and the effect of haemodilution per se. We recently published two studies on the effect of haemodilution with dextran 40 8 and albumin 9 . In this study, we used a similar methodology (rotational thromboelastometry) (ROTEM®, Pentapharm CO, Munich, Germany) and platelet function using multiple electrode aggregometry (Multiplate® Platelet Function Analyser, Dynabyte, Munich, Germany) to investigate the in vitro effects on coagulation of progressive haemodilution with 4% SG solution with equivalent dilutions with normal saline (NS) 0.9%.
Methods
After approval by Sydney Local Health District Ethics Review Committee (Protocol No. X15-0347 & HREC/15/RPAH/473) and with written informed consent, 20 healthy volunteers (ten male and ten female, aged between 23 and 49 years) were recruited. Exclusion criteria included known coagulation or haematological disorders, renal or liver disease and the use of anticoagulants or non-steroidal anti-inflammatory drugs within seven days of the study.
Blood sampling
Venous blood samples were obtained from an antecubital vein with minimal stasis using a 21G needle with Vacutainer system (Becton Dickinson, Franklin Lakes, NJ, USA) and placed into sample tubes containing EDTA, hirudin or citrate. Blood samples were collected into the EDTA tube (for full blood count), hirudin, and four citrate tubes in that order to exclude initial coagulation activation due to venepuncture and venous stasis from coagulation analysis.
Haemodilution
The blood samples were diluted in fixed proportion by 1:9 (10%), 1:4 (20%) and 1:1.5 (40%) with either 4% SG solution (Gelofusine) or 0.9% NS. The 10% haemodilution corresponds to a 70 kg subject with an estimated blood volume of 70 ml/ kg receiving approximately 500 ml of fluid. The upper limit of 40% is equivalent to the administration of 2 litres of SG in a 70 kg man, a clinical situation that could occur during resuscitation of a patient with grade IV haemorrhagic shock.
Haematological measurements
The routine laboratory measurements of haemoglobin concentration, white cell count, and platelet count were performed on each venous blood sample. On the undiluted and diluted blood samples, fibrinogen levels were measured in duplicate by the Clauss method using STA® Fibrinogen reagent with the STAR analyser (Diagnostica Stago, Asnieres, France).
ROTEM
Coagulation tests were performed on both the undiluted (control) and diluted blood samples using ROTEM, a pointof-care test that measures the viscoelastomeric properties of citrated whole blood for real-time assessment of clotting speed and strength. For the EXTEM assay, 300 μl of citrated blood was recalcified with 20 μl of Star-Tem® reagent containing 0.2 mol/l of CaCl 2 followed by the addition of recombinant tissue factor to trigger the extrinsic pathway (Ex-Tem® reagent). For the FIBTEM assay, 300 μl of citrated blood was mixed with 20 μl of Ex-Tem reagent plus 20 μl of cytochalasin D/DMSO (dimethyl sulfoxide) solution containing 0.2 mol/l CaCl 2 (Fib-Tem® reagent). Cytochalasin D is a platelet inhibitor, and hence the FIBTEM assay measures the formation of a fibrin clot only. The FIBTEM assay is well correlated with fibrinogen levels as measured by the Clauss method 10 . The ROTEM coagulation time (CT, time from commencement of analysis until the 2 mm amplitude is reached), maximum clot firmness (MCF, maximum curve amplitude, equivalent to maximum clot strength) and lysis at 30 minutes (LI30, percentage of clot remaining after 30 minutes) were measurements on both EXTEM and FIBTEM. The clot formation time (CFT, time elapsed from 2 mm to 20 mm amplitude) and the α-angle (angle of tangent to the curve at the 2 mm point measuring rate of initial clot formation) were only measurable with the EXTEM assay.
Multiple electrode aggregometry
Platelet activation causes platelet aggregation on artificial electrodes resulting in an increase in electrical resistance between them (impedance aggregometry). The multiple electrode aggregometry (Multiplate), based on impedance aggregometry, was used to assess platelet response to specific agonists in whole blood (WB) at the point of care. We measured the multiple electrode aggregometry response to four agonists (adenosine diphosphate, thrombin receptor activating peptide, collagen and ristocetin) to assess different pathways of platelet activation. Platelet aggregation was initiated by the addition of the following reagents: adenosine diphosphate test 0.2 mm, thrombin receptor activating peptide test (-6 [1 mm]), COLtest: collagen 100 µg/ml, and RISTO test: ristocetin 0.2 mg/ml. A change in electrical impedance was measured as an area under the curve over six minutes.
Statistical analysis
Statistical analysis was performed using SPPS Statistics version 20 software (IBM, New York, NY, USA). The data were analysed by analysis of variance (ANOVA) and a post hoc Tukey test was performed when a significant difference was detected. A P-value of <0.05 was considered statistically significant. Based on data from previous studies 8, 9, 11, 12 , ten subjects were estimated to provide a power of 80% at a five percent significance level to detect a 20% difference in thromboelastometric parameters from control samples.
Results
The baseline haemoglobin, platelet count, fibrinogen concentration and thromboelastometric parameters were within normal ranges. No significant differences in fibrinogen concentrations at equivalent haemodilutions with SG compared with NS were found.
Rotational thromboelastometry
The EXTEM CT (normal range 38 to 79 seconds) was not prolonged with increasing haemodilution at all levels with SG or NS (Figure 1 (Figure 3) . (Figures 5 and 6 ).
Multiple electrode (impedance) aggregometry
There were no differences in the area under the curve for the impedances measured in the adenosine diphosphate test, thrombin receptor activating peptide test, COLtest and RISTOtest between whole blood and blood diluted with either NS or SG at any level of dilution. No significant difference between the two fluids at all levels of dilution was observed ( Figure 7 ).
Discussion
We demonstrated that large amounts of haemodilution with SG solutions impaired coagulation in vitro to a greater extent than equivalent haemodilution with NS with no demonstrable platelet dysfunction (as assessed by impedance aggregometry). Substantial dilution of clotting factors with crystalloid is required before coagulation is impaired 13 . Haemodilution with SG significantly decreased FIBTEM MCF by 34.8% at 20% dilution whereas this occurred only at 40% haemodilution with NS. We showed that SG slowed clot formation, indicated by an increased EXTEM CFT, and reduced clot strength and fibrin formation at 40% haemodilution. We observed that platelet contribution to clot strength (EXTEM MCF-FIBTEM MCF) was not changed by SG and this was supported by the absence of altered platelet function demonstrated by impedance aggregometry.
The observed impairment of coagulation associated with SG was not entirely due to dilution of coagulation factors but another mechanism that impaired fibrinogen function. The mechanism by which SG impairs coagulation is yet to be established. Large molecules of colloids can interfere with fibrinogen 14 , Factor VIII and von Willebrand factor more than that predicted by haemodilution alone 15 . In addition, haemodilution might reduce thrombin generation and fibrin clot formation independently of each other 16 . Using a novel viscoelastic technique, the gel point, Lawrence et al, in an in vitro study, showed that gelatin, albumin and hydroxyethyl starch had a detrimental effect on clot microstructure 17 . Kind et al 18 showed a significant reduction in fibrinogen polymerisation with all colloids especially with hydroxyethyl starch. Substitution of fibrinogen improved the polymerisation of fibrinogen in dilutions with balanced gelatin solution but not with hydroxyethyl starch 18 . Thus the impairment of coagulation associated with haemodilution with SG may be mediated by an interaction between SG and fibrinogen resulting in impaired fibrinogen activity. This is suggested by our finding that haemodilution with gelatin altered the FIBTEM parameters to a greater extent.
The complexity of the coagulation system makes it . In addition, the endothelial effects, the pharmacokinetics, and the metabolism of gelatin were not included in our model. Other factors such as tissue damage and endothelial injury, as well as the stress response, were excluded in this in vitro model. Although the ROTEM provides an effective means of evaluating coagulation ex vivo, it does not assess the influence of intrinsic compensatory mechanisms or the interaction of blood components with the endothelium. Further, the ROTEM test is performed under static conditions and therefore does not take into account the complex interaction between the components of coagulation under various shear rates 20 . We did not assess the amount of residual citrate or ionised calcium present at each haemodilution, which may have implications on coagulation.
In this in vitro study, we have demonstrated that haemodilution greater than 40% with SG, which corresponds to a clinical situation that could occur during resuscitation of a patient with grade IV haemorrhagic shock, can impair coagulation. 
